Quality of Animal Experiments in Anti-Angiogenic Cancer Drug Development--A Systematic Review.

ABSTRACT: Translation from preclinical animal research to clinical bedside has proven to be difficult to impossible in many fields of research (e.g. acute stroke, ALS and HIV vaccination development) with oncology showing particularly low translation rates (5% vs. 20% for cardiovascular diseases). Several investigations on published preclinical animal research have revealed that apart from plain species differences, translational problems can arise from low study quality (e.g. study design) or non-representative experimental conditions (e.g. treatment schedule). This review assessed the published experimental circumstances and quality of anti-angiogenic cancer drug development in 232 in vivo studies. The quality of study design was often insufficient; at least the information published about the exp

SUBMITTER: Martic-Kehl MI 

PROVIDER: S-EPMC4589433 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature